CPHI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Login
View profile
Log out
Welcome back

Click below to sign in and see leads, RFIs or statistics

Sign in

Sign out
- Search Impressions
  
  3 287
- Page views
  
  324
- Request for information
  
  54

Brochure

11 Oct 2023

Cell Culture Services

PDF 1.3 MB

FUJIFILM Diosynth Biotechnologies is a leading provider of cell culture services for biologics, advancing anddelivering life changing therapies. We offer complete solutions for cell line development, process development,late phase activities, clinical and commercial manufacturing of a wide variety of biopharmaceuticals.

Content provided by our supplier

FUJIFILM Diosynth Biotechnologies

FUJIFILM Diosynth Biotechnologies

GB
2015

On CPHI since
1000 - 4999

Employees

Company types

Contract Service

Other Content from FUJIFILM Diosynth Biotechnologies (6)

News Fujifilm Diosynth Biotechnologies to expand biologics manufacturing capacity

As part of $850 million investment package, CDMO will double US cell culture production for recombinant vaccines and increase UK gene therapy production tenfold

30 Jun 2021
News Pandemic creates extra demand for CDMO services but investment decisions remain key to success

While the COVID-19 pandemic has created even greater demand for partnerships, CDMOs need to be aware that the needle has shifted, creating both opportunities and challenges and changing how the services industry does business

15 Jun 2021
News GSK to manufacture 60 million doses of Novavax vaccine for the UK

Pharma company will provide fill and finish manufacturing capacity at its Barnard Castle facility as early as the beginning of May 2021

29 Mar 2021
News Fujifilm names North Carolina as location for $2 billion large-scale cell manufacturing site

CDMO subsidiary Fujifilm Diosynth Biotechnologies will operate the site which is expected to be operational in 2025

19 Mar 2021
News Fujifilm invests $928 million to expand CDMO's biologics production facility in Denmark

Investment will double the site's drug substance manufacturing capacity and will expand its capabilities to include fill/finish, and enhance its current assembly, labeling and packaging services.

9 Jun 2020
News FDB to triple UK microbial production capacity as Fujifilm commits to $83 million investment

Fujifilm Diosynth Biotechnologies will triple microbial production capacity at its UK Teesside facility after joint owner Fujifilm Corporation pledged to invest 9 billion yen (USD83 million) in the biologics focused CDMO.

19 Mar 2020